These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19643598)

  • 41. Adjuvant treatment of colon cancer: what is next?
    Van Loon K; Venook AP
    Curr Opin Oncol; 2011 Jul; 23(4):403-9. PubMed ID: 21537178
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
    J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
    Stein A; Glockzin G; Wienke A; Arnold D; Edelmann T; Hildebrandt B; Hollerbach S; Illerhaus G; Königsrainer A; Richter M; Schlitt HJ; Schmoll HJ
    BMC Cancer; 2012 Aug; 12():356. PubMed ID: 22897915
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer.
    Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ueno M; Yamaguchi T
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):322-9. PubMed ID: 23915091
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Mar; 12(3):356-61. PubMed ID: 17405901
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Transition of chemotherapy for metastatic colorectal cancer and recent advances].
    Muro K
    Nihon Rinsho; 2010 Jun; 68(6):1143-9. PubMed ID: 20535969
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
    Kabbinavar FF; Hurwitz HI; Yi J; Sarkar S; Rosen O
    J Clin Oncol; 2009 Jan; 27(2):199-205. PubMed ID: 19064978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
    Allegra CJ; Yothers G; O'Connell MJ; Sharif S; Colangelo LH; Lopa SH; Petrelli NJ; Goldberg RM; Atkins JN; Seay TE; Fehrenbacher L; O'Reilly S; Chu L; Azar CA; Wolmark N
    J Clin Oncol; 2009 Jul; 27(20):3385-90. PubMed ID: 19414665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups.
    Macedo LT; da Costa Lima AB; Sasse AD
    BMC Cancer; 2012 Mar; 12():89. PubMed ID: 22414244
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.
    Saif MW
    Expert Opin Biol Ther; 2013 Nov; 13(11):1489-93. PubMed ID: 24050123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
    Mishima H; Oba K; Sakamoto J; Muro K; Yoshino T; Hyodo I; Maehara Y
    Jpn J Clin Oncol; 2012 Feb; 42(2):134-8. PubMed ID: 22167662
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Always look at the bright side of drugs?
    Nygren P
    Acta Oncol; 2015 Feb; 54(2):145-7. PubMed ID: 25608927
    [No Abstract]   [Full Text] [Related]  

  • 55. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
    Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
    J Clin Oncol; 2015 Apr; 33(10):1112-8. PubMed ID: 25691669
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Biotherapy in colorectal cancer].
    Des Guetz G
    J Chir (Paris); 2005; 142(5):291-6. PubMed ID: 16292207
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current status of second-line therapy for metastatic colorectal cancer.
    Rothenberg ML
    Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S16-21. PubMed ID: 15212701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
    Saam J; Critchfield GC; Hamilton SA; Roa BB; Wenstrup RJ; Kaldate RR
    Clin Colorectal Cancer; 2011 Sep; 10(3):203-6. PubMed ID: 21855044
    [No Abstract]   [Full Text] [Related]  

  • 59. [Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer].
    Horinouchi Y; Sakurada T; Nakamura T; Tajima S; Nishisako H; Abe S; Teraoka K; Kujime T; Kawazoe K; Minakuchi K
    Yakugaku Zasshi; 2011; 131(8):1251-7. PubMed ID: 21804330
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
    Sharma MR; Gray E; Goldberg RM; Sargent DJ; Karrison TG
    J Clin Oncol; 2015 Jan; 33(1):36-41. PubMed ID: 25349295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.